Hillevax Market Capitalization from 2010 to 2024
| HLVX Stock | USD 1.91 0.03 1.55% |
Check Hillevax financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Hillevax's main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.1 M, Interest Expense of 1.9 M or Selling General Administrative of 28 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 2.58. Hillevax financial statements analysis is a perfect complement when working with Hillevax Valuation or Volatility modules.
Hillevax | Market Capitalization |
Latest Hillevax's Market Capitalization Growth Pattern
Below is the plot of the Market Cap of Hillevax over the last few years. It is Hillevax's Market Cap historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Hillevax's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported 96.62 M | 10 Years Trend |
|
Market Cap |
| Timeline |
Hillevax Market Capitalization Regression Statistics
| Arithmetic Mean | 578,637,035 | |
| Geometric Mean | 577,597,259 | |
| Coefficient Of Variation | 6.10 | |
| Mean Deviation | 16,575,609 | |
| Median | 576,354,952 | |
| Standard Deviation | 35,273,831 | |
| Sample Variance | 1244.2T | |
| Range | 169.9M | |
| R-Value | 0.03 | |
| Mean Square Error | 1339.1T | |
| R-Squared | 0.0007 | |
| Significance | 0.93 | |
| Slope | 203,953 | |
| Total Sum of Squares | 17419.4T |
Hillevax Market Capitalization History
About Hillevax Financial Statements
Hillevax investors use historical fundamental indicators, such as Hillevax's Market Capitalization, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Hillevax. Please read more on our technical analysis and fundamental analysis pages.
HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines. It is developing HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. Hillevax operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 15 people.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Hillevax Stock Analysis
When running Hillevax's price analysis, check to measure Hillevax's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Hillevax is operating at the current time. Most of Hillevax's value examination focuses on studying past and present price action to predict the probability of Hillevax's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Hillevax's price. Additionally, you may evaluate how the addition of Hillevax to your portfolios can decrease your overall portfolio volatility.